EuCorVac-19
Sign in to saveEuCorVac-19 is a COVID-19 vaccine candidate developed by EuBiologics Co.
In the Vinony graph
Within Vinony's link graph, EuCorVac-19 is referenced by 1,278 other articles, and connects out to SARS-CoV-2, Gam-COVID-Vac and COVID-19 pandemic in Italy.
It sits within the topics Chemical pages without ChemSpiderID, Chemical pages without DrugBank identifier and Clinical trials related to COVID-19.
Its subject is documented across 10 Wikipedia language editions.
Key facts
- Drug.type
- vaccine
- Drug.target
- SARS-CoV-2
- Drug.vaccine_type
- protein
- Drug.routes_of_administration
- Intramuscular
- Drug.CAS_number
- 2696268-42-3
via Wikipedia infobox
~1 min read
Encyclopedic overview
4 sectionsContents
- Clinical trials
- Phase I/II
- Phase III
- References
EuCorVac-19 is a COVID-19 vaccine candidate developed by EuBiologics Co.
== Clinical trials == === Phase I/II === EuBiologics Co., Ltd started the study on February 23, 2021. The study is titled "Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults" As of April 26, 2021, the trial is ongoing, and participants are being accepted. It has an expected primary completion date of March 2022. The study is anticipated to be completed in January 2023.
Excerpted from Wikipedia’s “EuCorVac-19” article, available under the CC BY-SA 4.0 licence.